# IV Administration of ChromaDex's Niagen® as Compared to NAD+

> **NCT06382688** · NA · UNKNOWN · sponsor: **Nutraceuticals Research Institute** · enrollment: 53 (actual)

## Conditions studied

- Healthy Aging

## Interventions

- **DIETARY_SUPPLEMENT:** NAD+ (nicotinamide adenine dinucleotide) IV
- **DIETARY_SUPPLEMENT:** Niagen® (nicotinamide riboside) IV
- **DIETARY_SUPPLEMENT:** Niagen® (nicotinamide riboside) oral
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06382688
- **Lead sponsor:** Nutraceuticals Research Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11-13
- **Primary completion:** 2024-03-08
- **Final completion:** 2024-08-31
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2024-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06382688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06382688, "IV Administration of ChromaDex's Niagen® as Compared to NAD+". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06382688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*